Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.

Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV.

Br J Cancer. 2005 May 9;92(9):1626-35.

2.

Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.

Kocabaş NA, Sardaş S, Cholerton S, Daly AK, Elhan AH, Karakaya AE.

Cell Biochem Funct. 2005 Jan-Feb;23(1):73-6.

PMID:
15386537
3.

N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population.

Kocabaş NA, Sardaş S, Cholerton S, Daly AK, Karakaya AE.

Int J Toxicol. 2004 Jan-Feb;23(1):25-31.

PMID:
15162844
4.

Analysis of cytochrome P450 polymorphisms.

Daly AK, Monkman SC, Smart J, Steward A, Cholerton S.

Methods Mol Biol. 1998;107:405-22. No abstract available.

PMID:
14577249
5.

Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population.

Kocabaş NA, Sardaş S, Cholerton S, Daly AK, Karakaya AE.

Arch Toxicol. 2002 Nov;76(11):643-9. Epub 2002 Aug 21.

PMID:
12415427
6.

Catechol-O-methyltransferase (COMT) genetic polymorphism in a Turkish population.

Kocabaş NA, Karakaya AE, Cholerton S, Sardaş S.

Arch Toxicol. 2001 Sep;75(7):407-9.

PMID:
11693181
7.

Determination of coumarin metabolism in Turkish population.

Cok I, Aygün Kocabaş N, Cholerton S, Karakaya AE, Sardaş S.

Hum Exp Toxicol. 2001 Apr;20(4):179-84.

PMID:
11393269
8.

The effect of fluconazole on cyclophosphamide metabolism in children.

Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, Pearson AD, Boddy AV.

Drug Metab Dispos. 1999 Mar;27(3):417-21.

PMID:
10064575
9.

Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population.

Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S.

Pharmacogenetics. 1998 Apr;8(2):125-8.

PMID:
10022750
10.

Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6.

Hadidi H, Irshaid Y, Vågbø CB, Brunsvik A, Cholerton S, Zahlsen K, Idle JR.

Eur J Clin Pharmacol. 1998 Jul;54(5):437-41.

PMID:
9754990
11.
12.

CYP2D6 genotype and smoking behaviour in cigarette smokers.

Boustead C, Taber H, Idle JR, Cholerton S.

Pharmacogenetics. 1997 Oct;7(5):411-4. No abstract available.

PMID:
9352579
13.

Trimethylamine N-oxidation in Turkish women with bacterial vaginosis.

Sardas S, Akyol D, Green RL, Mellon T, Gökmen O, Cholerton S.

Pharmacogenetics. 1996 Oct;6(5):459-63.

PMID:
8946478
14.

CYP2D6 genotypes in cigarette smokers and non-tobacco users.

Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR.

Pharmacogenetics. 1996 Jun;6(3):261-3. No abstract available.

PMID:
8807667
15.

Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid.

Monkman SC, Ellis JS, Cholerton S, Thomason JM, Seymour RA, Idle JR.

J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):360-4.

PMID:
8738044
16.

A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, et al.

Am J Hum Genet. 1995 Sep;57(3):651-60.

17.

The N-oxidation of trimethylamine in a Jordanian population.

Hadidi HF, Cholerton S, Atkinson S, Irshaid YM, Rawashdeh NM, Idle JR.

Br J Clin Pharmacol. 1995 Feb;39(2):179-81.

18.

Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.

Daly AK, Cholerton S, Armstrong M, Idle JR.

Environ Health Perspect. 1994 Nov;102 Suppl 9:55-61.

19.

Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.

Hadidi HF, Cholerton S, Monkman SC, Armstrong M, Irshaid YM, Rawashdeh NM, Daly AK, Idle JR.

Pharmacogenetics. 1994 Jun;4(3):159-61. No abstract available.

PMID:
7920696
20.

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH, et al.

Biochem Pharmacol. 1994 Mar 29;47(7):1157-63.

PMID:
8161344
21.

Poor metabolisers of nicotine and CYP2D6 polymorphism.

Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, Leathart J, Daly AK, Idle JR.

Lancet. 1994 Jan 1;343(8888):62-3. No abstract available.

PMID:
7905082
22.

Metabolic polymorphisms.

Daly AK, Cholerton S, Gregory W, Idle JR.

Pharmacol Ther. 1993 Feb-Mar;57(2-3):129-60. Review.

PMID:
8361990
23.

The pharmacogenetics of chemical carcinogenesis.

Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, Daly AK, Ellis J, Gregory W, Hadidi H, et al.

Pharmacogenetics. 1992 Dec;2(6):246-58. Review.

PMID:
1306125
24.

The role of individual human cytochromes P450 in drug metabolism and clinical response.

Cholerton S, Daly AK, Idle JR.

Trends Pharmacol Sci. 1992 Dec;13(12):434-9. Review.

PMID:
1293869
25.

Mutant debrisoquine hydroxylation genes in Parkinson's disease.

Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR.

Lancet. 1992 Apr 25;339(8800):1017-8.

PMID:
1349052
26.
27.

Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers.

Rothwell M, Rampling MW, Cholerton S, Sever PS.

Br J Haematol. 1991 Nov;79(3):500-3.

PMID:
1751379
28.

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.

Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, Smith RL.

Chirality. 1991;3(1):14-8.

PMID:
2039678
29.

Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine.

Edwards C, Monkman S, Cholerton S, Rawlins MD, Idle JR, Ferner RE.

Br J Clin Pharmacol. 1990 Dec;30(6):889-91.

30.

Pharmacokinetics and toxic effects of nifedipine in massive overdose.

Ferner RE, Monkman S, Riley J, Cholerton S, Idle JR, Bateman DN.

Hum Exp Toxicol. 1990 Sep;9(5):309-11.

PMID:
2261244
31.

Acute changes in atherogenic and thrombogenic factors with cessation of smoking.

Feher MD, Rampling MW, Brown J, Robinson R, Richmond W, Cholerton S, Bain BJ, Sever PS.

J R Soc Med. 1990 Mar;83(3):146-8.

32.

An investigation of the pharmacological response to vitamin K1 in the rabbit.

Winn MJ, Cholerton S, Park BK.

Br J Pharmacol. 1988 Aug;94(4):1077-84.

33.

The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, Preston FE, Park BK.

Br J Clin Pharmacol. 1988 Jan;25(1):1-7.

34.

Enantiomers of warfarin and vitamin K1 metabolism.

Choonara IA, Haynes BP, Cholerton S, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1986 Dec;22(6):729-32.

35.

Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1986 Mar;21(3):271-7.

36.

Problems of anticoagulation with warfarin in hyperthyroidism.

Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD.

Q J Med. 1986 Jan;58(225):43-51.

PMID:
3704105
37.

Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients.

Choonara IA, Scott AK, Haynes BP, Cholerton S, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1985 Dec;20(6):643-8.

Supplemental Content

Loading ...
Support Center